CV Lattes
ORCID
Abstract
Acute myeloid leukemia (AML) is an aggressive disease and corresponds to the lower survival rate among leukemias types. Only 40% of the patients under 60 y.o. survive more than 5 years and, in patients over 60 y.o., the chemotherapy does not provide the cure and cause death in less than a year. Thus, revealing the urgent seek for new treatments. The BRD4 (Bromodomain-containing protein 4)…